Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03597581
Title A Study of RGX-202-01 as Combination Therapy in 2nd Line RAS Mutant Advanced Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Inspirna, Inc.

colorectal adenocarcinoma



Fluorouracil + Irinotecan + Leucovorin + RGX202

Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + RGX202

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Terminated Duarte California 91010 United States Details
Cedars-Sinai Medical Center Recruiting Los Angeles California 90048 United States Details
UCLA Department of Medicine Recruiting Santa Monica California 90404 United States Details
Memorial Sloan Kettering Cancer Center Recruiting New York New York 10065 United States Details
University of North Carolina Chapel Hill Recruiting Chapel Hill North Carolina 27599 United States Details
Tennessee Oncology Recruiting Nashville Tennessee 37203 United States Details
Mary Crowley Cancer Research Terminated Dallas Texas 75230 United States Details
*Shaded cells indicate that there was no data available from for the field